Riskpilot← Back to searchSign inGet full accessBOHNE ASKØY AS
ASActiveOrg 918165258Romledalen 51, 5310 HauglandshellaManufacture of pharmaceutical preparations · NACE 2120Est. 20160 employees
Revenue 2024
NOK 0
EBITDA margin
—
-145% vs 2023
Equity ratio
-6375550.0%
Financial strength
Net profit 2024
NOK -30K
+98% vs 2023
| Revenue | NOK 0 | — |
| EBITDA | NOK -30K | -145% |
| Net profit | NOK -30K | +98% |
| Total assets | NOK 6 | -100% |
| Equity | NOK -383K | -8% |
| Employees | 0 | — |
Legal name
BOHNE ASKØY AS
Org number
918165258
Legal form
Aksjeselskap
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
8. desember 2016
Share capital
NOK 33 444
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styret i fellesskap.
Company purpose
Utvikling av legemidler.
Address
Romledalen 51, 5310 Hauglandshella
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 10 | 0 | 0 | 0 | 0 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 |
| EBITDA | −20 | −123 | −19 | −12 | −30 |
| Depreciation & amort. | −0 | −0 | −0 | −1 203 | −0 |
| EBIT | −20 | −123 | −19 | −1 215 | −30 |
| Net financials | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | −20 | −123 | −19 | −1 215 | −30 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −20 | −123 | −19 | −1 215 | −30 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 1 117 | 1 169 | 1 209 | 6 | 0 |
| Equity | 1 004 | 881 | 862 | −353 | −383 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 113 | 287 | 347 | 359 | 383 |
| Total debt | 113 | 287 | 347 | 359 | 383 |
EBITDA margin
-2953400.0%
This company
15.8%
Market median
-18692505% vs market
20202024
Equity ratio
-6375550.0%
This company
38.2%
Market median
-16690021% vs market
20202024
Return on equity
-2953300.0%
This company
18.4%
Market median
-16050643% vs market
20202024
Net profit margin
-2953300.0%
This company
8.1%
Market median
-36460594% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
1.00×
This company
0.62×
Market median
-61% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
ØB Chief Executive Officer | Chief Executive Officer | 2016 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2016 | |
| Chairman | 2016 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 45.65% | 45.65% | 2022 | |
| Individual | 1.6% | 1.6% | 2024 | |
| Individual | 1.6% | 1.6% | 2022 | |
| Individual | 1.6% | 1.6% | 2024 | |
| Individual | 1.5% | 1.5% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of BOHNE ASKØY AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Øyvind Bohne | Chief Executive Officer | 0 companies |
| Roman Bohne | Board of Directors | 0 companies |
| Victoria Jurievna Berdikova Bohne | Chairman | 0 companies |